PubRank

S Broder

Author PubWeight™ 378.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The sequence of the human genome. Science 2001 101.55
2 A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981 10.92
3 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985 10.71
4 Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986 8.48
5 Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet 1974 8.13
6 Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A 1986 6.63
7 Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A 1987 5.17
8 Molecular targets for AIDS therapy. Science 1990 4.28
9 Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science 1986 4.17
10 Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med 1975 3.81
11 A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med 1984 3.41
12 Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 1988 3.01
13 Strategies for antiviral therapy in AIDS. Nature 1987 2.95
14 Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987 2.92
15 In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science 1989 2.70
16 Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 1984 2.70
17 Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A 1989 2.62
18 CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med 1991 2.35
19 The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest 1976 2.32
20 Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993 2.27
21 Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989 2.17
22 Fraud in breast-cancer trials. N Engl J Med 1994 2.16
23 NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med 1984 2.10
24 Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987 2.10
25 Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990 2.02
26 Suppressor cells in the regulation of the immune response. Prog Clin Immunol 1977 1.99
27 Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989 1.99
28 Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A 1987 1.96
29 Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A 1993 1.92
30 Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 1991 1.91
31 Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med 1987 1.88
32 Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990 1.87
33 Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol 1982 1.85
34 Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem 1988 1.82
35 Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol 1978 1.79
36 Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med 1978 1.78
37 Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science 1984 1.74
38 Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest 1986 1.70
39 Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry 1989 1.70
40 Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency. Trans Assoc Am Physicians 1976 1.59
41 Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983 1.58
42 Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1987 1.57
43 Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1986 1.56
44 Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995 1.56
45 Stability of HL-A and appearance of other antigens (LIVA) at the surface of lymphoblasts grown in vitro. Haematologica 1969 1.53
46 3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem 1987 1.53
47 Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988 1.51
48 Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. AIDS Res Hum Retroviruses 1992 1.50
49 Implications of the human genome for understanding human biology and medicine. JAMA 2001 1.47
50 Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol 1979 1.46
51 The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma. Fed Proc 1976 1.46
52 The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988 1.45
53 Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. Nature 1983 1.42
54 Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990 1.42
55 Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 1988 1.38
56 Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1982 1.37
57 Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 1985 1.35
58 The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989 1.33
59 Targeted therapy of human immunodeficiency virus-related disease. FASEB J 1991 1.33
60 Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem 1988 1.32
61 Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990 1.31
62 Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. N Engl J Med 1978 1.30
63 Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients. Blood 1981 1.27
64 Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem 1990 1.27
65 Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989 1.27
66 The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 1988 1.26
67 Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). Gene 1988 1.26
68 Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res 1983 1.25
69 Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr 1990 1.24
70 Pharmacological inhibition of infectivity of HTLV-III in vitro. Cancer Res 1985 1.24
71 Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A 1986 1.24
72 Inhibitory activity of antibodies to human Ia-like determinants: comparison of intact and pepsin-digested antibodies. J Immunol 1983 1.23
73 Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro. AIDS Res Hum Retroviruses 1988 1.22
74 Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. J Clin Invest 1983 1.21
75 The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. Mol Pharmacol 1987 1.21
76 Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. Ann Intern Med 1976 1.21
77 Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine. Biochem Biophys Res Commun 1986 1.19
78 Polyclonal activation of human B lymphocytes by Nocardia water soluble mitogen (NWSM). Immunol Rev 1979 1.19
79 Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI). AIDS Res Hum Retroviruses 1990 1.17
80 Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage. Blood 1994 1.16
81 Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology 1989 1.16
82 Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology 1981 1.16
83 Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Muscle Nerve 1989 1.15
84 Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1988 1.13
85 Suppressor T cells in the pathogenesis of hypogammaglobulinemia associated with a thymoma. Trans Assoc Am Physicians 1975 1.13
86 Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci 1990 1.12
87 Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood 1991 1.12
88 Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem Biophys Res Commun 1986 1.11
89 Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Int J Cancer 1986 1.10
90 Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A 1987 1.10
91 Molecular foundations of cancer: new targets for intervention. Nat Med 1995 1.10
92 Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30). J Exp Med 1980 1.09
93 Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J Exp Med 1990 1.09
94 Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986 1.09
95 Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med 1983 1.09
96 X-linked hypogammaglobulinemia and isolated growth hormone deficiency. N Engl J Med 1980 1.07
97 Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression. Adv Intern Med 1984 1.05
98 T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989 1.05
99 Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. J Clin Invest 1987 1.05
100 Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. AIDS 1997 1.04
101 Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993 1.03
102 Suppressor cells in neoplastic disease. J Natl Cancer Inst 1978 1.03
103 Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Mol Pharmacol 1991 1.03
104 Cutaneous T-cell lymphomas. Semin Oncol 1980 1.02
105 Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. Drug Metab Dispos 1993 1.01
106 Transformation and cytopathogenic effect in an immune human T-cell clone infected by HTLV-I. Science 1984 0.99
107 Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. Pharmacol Ther 1989 0.98
108 Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I. J Clin Invest 1986 0.98
109 Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res 1991 0.98
110 In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells. J Infect Dis 1991 0.97
111 Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1990 0.97
112 The suppressor-cell network in cancer (first of two parts). N Engl J Med 1978 0.97
113 Serum immunoglobulin E levels in patients with neoplastic disease. J Immunol 1974 0.96
114 Fc-IgM and Fc-IgG receptors on human circulating B lymphocytes. J Immunol 1978 0.96
115 Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. J Nucl Med 1989 0.95
116 Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. Calcif Tissue Int 2001 0.95
117 Sequence analysis of the human genome: implications for the understanding of nervous system function and disease. Arch Neurol 2001 0.95
118 2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 1987 0.93
119 AIDS therapies. Sci Am 1988 0.93
120 Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells. J Exp Med 1986 0.93
121 In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrob Agents Chemother 1990 0.92
122 2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem Pharmacol 1987 0.92
123 Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998 0.92
124 The suppressor-cell network in cancer (second of two parts). N Engl J Med 1978 0.91
125 Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro. Antimicrob Agents Chemother 1990 0.90
126 Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues. J Med Chem 1987 0.90
127 In vitro functions of human T cells expressing Fc-IgG or Fc-IgM receptors. Immunol Rev 1981 0.89
128 Infection of human T lymphotropic virus-I-specific immune T cell clones by human T lymphotropic virus-I. J Clin Invest 1986 0.89
129 Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection. Am J Med 1989 0.89
130 Evolution of a lymphoma with helper T cell characteristics in Sézary syndrome. Blood 1978 0.89
131 Suppression of retroviral propagation and disease by suramin in murine systems. Proc Natl Acad Sci U S A 1985 0.88
132 Corticosteroid-responsive intestinal lymphangiectasia secondary to an inflammatory process. N Engl J Med 1979 0.88
133 Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res Hum Retroviruses 1989 0.88
134 1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus. J Med Chem 1989 0.87
135 Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 1991 0.87
136 Neoplasms of immunoregulatory cells. Am J Clin Pathol 1979 0.87
137 Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells. N Engl J Med 1981 0.87
138 Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. Antisense Res Dev 1992 0.86
139 Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents. Nucleic Acids Res 1990 0.86
140 Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992 0.86
141 2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine. Mol Pharmacol 1990 0.86
142 Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993 0.85
143 Developmental therapeutics and the acquired immunodeficiency syndrome. Ann Intern Med 1987 0.84
144 Human T-cell leukemia viruses (HTLV): a unique family of pathogenic retroviruses. Annu Rev Immunol 1985 0.84
145 Current concepts in immunoregulatory T-cell neoplasms. Cancer Treat Rep 1979 0.84
146 Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995 0.84
147 The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions. J Clin Invest 1977 0.84
148 Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine. Rev Infect Dis 1990 0.83
149 Immunologic enhancement of tumor xenografts by pepsin-degraded immunoglobulin. Science 1968 0.83
150 Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity. Nucleic Acids Res 1989 0.83
151 Immunoregulatory functions of cultured human T lymphocytes. Trans Assoc Am Physicians 1980 0.83
152 1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus. J Med Chem 1988 0.82
153 Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 1998 0.82
154 Synthesis and anti-HIV activity of isonucleosides. J Med Chem 1992 0.82
155 Chemotherapy for lymphoma in a patient with common variable immunodeficiency: case report, literature review, and recommendations for chemotherapy in immunodeficient patients. Arch Intern Med 1982 0.82
156 Pathogenic human retroviruses. N Engl J Med 1988 0.82
157 High molecular weight antigens present on human T cells. Proc Natl Acad Sci U S A 1980 0.82
158 Challenges in the therapy of HIV infection. Immunol Today 1993 0.81
159 Immunologic issues in anti-retroviral therapy. Immunol Today 1990 0.81
160 Microbial disease in humans: A genomic perspective. Mol Diagn 2001 0.81
161 Characterization of lymphoblast Fc receptor expression in acute lymphoblastic leukemia. Blood 1979 0.80
162 The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention. Leuk Lymphoma 1992 0.80
163 HIV interaction with sperm. AIDS 1994 0.80
164 Fc receptors on human T lymphocytes. V: Effects of colchicine and cytochalasin B on Fc receptor expression. J Immunol 1980 0.80
165 New directions in molecular medicine. Cancer Res 1994 0.80
166 Controlled trial methodology and progress in treatment of the acquired immunodeficiency syndrome (AIDS). A quid pro quo. Ann Intern Med 1989 0.80
167 Challenges in the therapy of HIV infection. Trends Pharmacol Sci 1993 0.80
168 Homologous artificial insemination after long-term semen cryopreservation. Fertil Steril 1981 0.80
169 Reactivity of lupus erythematosus antibodies with leukemic helper T cells. J Invest Dermatol 1978 0.79
170 Strategies for the combination therapy of HIV infection. J Acquir Immune Defic Syndr 1990 0.79
171 Cytogenetic studies in human T-cell lymphoma virus (HTLV)-positive leukemia-lymphoma in the United States. J Natl Cancer Inst 1985 0.79
172 From the National Institutes of Health. JAMA 1992 0.79
173 Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. AIDS Res Hum Retroviruses 1990 0.79
174 Therapy of AIDS and AIDS-associated neoplasms. Cancer Chemother Biol Response Modif 1992 0.78
175 Antiretroviral chemotherapy against human immunodeficiency virus (hiv) infection: perspective for therapy of hepatitis B virus infection. Cancer Detect Prev 1989 0.78
176 A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis B. Hepatology 1992 0.78
177 Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995 0.78
178 Human T-cell leukemia/lymphoma viruses (HTLV): a unique family of pathogenic retroviruses. Curr Top Microbiol Immunol 1985 0.78
179 Follow-up of neuropathy from 2',3'-dideoxycytidine. Lancet 1988 0.78
180 Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS. J Infect Dis 1993 0.77
181 Protein-losing enteropathies in malignancy. Ann N Y Acad Sci 1974 0.77
182 T cell proliferation and ablation. A biologic spectrum of abnormalities induced by the human T cell lymphotropic virus group. Prog Allergy 1986 0.77
183 2',3'-Dideoxyadenosine is selectively toxic for TdT-positive cells. Blood 1988 0.77
184 Cigarette advertising and corporate responsibility. JAMA 1992 0.77
185 Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro. Princess Takamatsu Symp 1984 0.77
186 A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis 1993 0.76
187 Immune T cells reactive against human T-cell leukaemia/lymphoma virus. Lancet 1984 0.76
188 Regulation of the humoral immune response: from immunoglobulin genes to regulatory T cell networks. Fed Proc 1983 0.76
189 HIV-associated non-Hodgkin's lymphomas. Ann Oncol 1991 0.75
190 Neoplasms of immunoregulatory T cells in clinical investigation. J Invest Dermatol 1980 0.75
191 Winning the war on cancer. N Engl J Med 1997 0.75
192 Abnormalities of immunoregulatory cells in immunodeficiency disease and cancer. Prog Clin Biol Res 1981 0.75
193 Regression of a T-cell lymphoma after administration of antithymocyte globulin. Ann Intern Med 1978 0.75
194 Therapy of acquired immunodeficiency syndrome. Cancer Chemother Biol Response Modif 1987 0.75
195 Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995 0.75
196 F(ab') 2 -like immunoglobulin fragments in urines from patients with systemic lupus erythematosus. J Lab Clin Med 1972 0.75
197 Oncology. JAMA 1993 0.75
198 AIDS and related disorders. Cancer Chemother Biol Response Modif 1988 0.75
199 Progress in the development of antiviral therapy for HTLV-III-associated diseases. Important Adv Oncol 1987 0.75
200 Samuel Broder, MD, reflects on the 30th anniversary of the National Cancer Act. Interviewed by Brian Vastag. JAMA 2001 0.75
201 Suramin and function of the adrenal cortex. Ann Intern Med 1986 0.75
202 Treatment of acquired immunodeficiency syndrome. Cancer Chemother Biol Response Modif 1990 0.75
203 The immunology of HIV infection: implications for therapy. AIDS Res Hum Retroviruses 1992 0.75
204 Fusidic acid, HIV, and host cell toxicity. Lancet 1988 0.75
205 Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development. J Enzyme Inhib 1992 0.75
206 Fc IgM receptors on human lymphoblastoid B cell lines. Eur J Immunol 1978 0.75
207 Cellular regulation of immune function. J Allergy Clin Immunol 1980 0.75
208 Therapy of AIDS and AIDS-related tumors. Cancer Chemother Biol Response Modif 1991 0.75
209 Progress and challenges in the global effort against cancer. J Cancer Res Clin Oncol 1991 0.75
210 Acquired immune deficiency syndrome (AIDS) and Kaposi's sarcoma: clinical relationship between immunodeficiency disease and cancer. Important Adv Oncol 1985 0.75
211 Strategies for measurement of different aspects of self-disclosure. Psychol Rep 1977 0.75
212 Interactions between radioresistant T cells from plasmacytoma-bearing mice and radiosensitive T cells from normal mice leading to suppression. Hematol Oncol 1984 0.75
213 Unusual clonal evolution in a case of chronic myelogenous leukemia. Acta Haematol 1976 0.75
214 Alpha, beta- and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine-5'-triphosphate. Correlation between affinity for reverse transcriptase, susceptibility to hydrolysis by phosphodiesterases and anti-retrovirus activity. Biochem Pharmacol 1988 0.75
215 Antiviral therapy against HIV infection. J Am Acad Dermatol 1990 0.75
216 The molecular pathology of lymphomas. J Clin Oncol 1986 0.75
217 Oncology. JAMA 1991 0.75
218 The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. Ann Oncol 1991 0.75
219 Oncology and hematology. JAMA 1994 0.75
220 Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection. J Am Acad Dermatol 1989 0.75
221 Blocking activity of non-cytotoxic F (ab')2 tumor cell antibody fragments. Proc Soc Exp Biol Med 1968 0.75
222 Oncology. JAMA 1992 0.75
223 Implications of the discovery of HTLV-III for the treatment of AIDS. Cancer Res 1985 0.75
224 Protein-losing enteropathy in malignancy. Curr Concepts Nutr 1977 0.75
225 Normal and malignant T cells in the regulation of inflammation and immunity. Agents Actions Suppl 1980 0.75